Ozempic: arrival of generics lowers prices but raises warnings

Ozempic: arrival of generics lowers prices but raises warnings

Health Canada has approved the first two generic versions of semaglutide, the active ingredient in Ozempic, a decision expected to significantly lower the drug’s cost while raising concerns among some healthcare professionals.

Originally used to treat type 2 diabetes, this injectable medication is also widely prescribed off-label for weight loss. The new generics are produced by Dr. Reddy’s Laboratories and Canadian company Apotex, making Canada the first G7 country to authorize such alternatives.

With the recent expiration of the patent, the arrival of generics could dramatically reduce prices. Currently, Ozempic costs between $200 and $400 per month and is not always covered when used for weight loss. Depending on how many generics enter the market, prices could drop to a fraction of the brand-name cost.

Healthcare professionals welcome the improved accessibility but emphasize that semaglutide is not a miracle solution. Its use must be combined with lifestyle changes and proper medical supervision.

However, several physicians caution against unsupervised use, particularly for cosmetic purposes. Side effects such as nausea, vomiting, and mood changes have been reported, while long-term data remain limited.

Canada is now among the world’s largest consumers of Ozempic, with public spending on the drug increasing significantly in recent years.